Holen Sie sich die Stockscreener-App
10.28
8.32%
0.79
Handel nachbörslich:
10.33
0.05
+0.49%
Schlusskurs vom Vortag:
$9.49
Offen:
$9.56
24-Stunden-Volumen:
50,380
Relative Volume:
0.40
Marktkapitalisierung:
$152.23M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-13.01
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
+12.97%
1M Leistung:
+18.30%
6M Leistung:
-10.69%
1J Leistung:
-68.47%
1-Tages-Spanne:
$9.56
$10.35
1-Wochen-Bereich:
$9.11
$10.35
52-Wochen-Spanne:
$7.65
$34.90
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
10.28 | 134.75M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
What analysts say about Lyell Immunopharma Inc. stockFree Buy/Sell Signal Notifications - jammulinksnews.com
Is Lyell Immunopharma Inc. a good long term investmentFree Predictions - jammulinksnews.com
Lyell Immunopharma's LYL314: A High-Risk, High-Reward Catalyst in the CAR T-Cell Space - AInvest
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement (LYEL) - Seeking Alpha
Lyell Immunopharma Inc. Stock Analysis and ForecastExceptional profit margins - PrintWeekIndia
Lyell Immunopharma registers 625,000 shares for resale - MSN
What drives Lyell Immunopharma Inc. stock priceSuperior stock growth - printweek.in
why lyell immunopharma inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 5.9% – What’s Next? - Defense World
Why Lyell Immunopharma Inc. stock attracts strong analyst attentionShort Term High Return Strategy - Newser
What makes Lyell Immunopharma Inc. stock price move sharplyPredictable High Return Trades - Newser
How Lyell Immunopharma Inc. stock performs during market volatilityFree Stock Market Trend Analysis - Newser
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher – What’s Next? - Defense World
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
Lyell reports new clinical data from trial of large B-cell lymphoma therapy - Yahoo Finance
Lyell’s lymphoma therapy shows high response rate in trial - Investing.com
Lyell’s lymphoma therapy shows high response rate in trial By Investing.com - Investing.com Nigeria
Lyell Immunopharma Announces Promising CAR T-Cell Trial Data - TipRanks
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial - marketscreener.com
Lyell Immunopharma (LYEL) Releases Promising Results from LYL314 Trial | LYEL Stock News - GuruFocus
Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma - MarketScreener
Lyell Immunopharma Announces Positive New Clinical Data - GlobeNewswire
Lyell Immunopharma Stock Soars 23.11% Post Reverse Split - AInvest
Lyell Immunopharma (LYEL) Strengthens Leadership Team with Key A - GuruFocus
Lyell Immunopharma (LYEL) Announces Key Executive Appointments | LYEL Stock News - GuruFocus
Lyell Immunopharma Expands Board, Appoints New Director - TipRanks
Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments - marketscreener.com
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Lyell Immunopharma Strengthens Leadership: Key Hires from BMS, Amgen Shape CAR T-cell Future - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Raised to Hold at Wall Street Zen - Defense World
From Collapse to Comeback: Lyell Immunopharma’s Stock Surge Signals Turning Point - FXLeaders
From Collapse to Comeback: Lyell Immunopharma's Stock Surge Signals Turning Point—Cancer Breakthrough? - FXLeaders
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):